Search research articles
Contact Us
Filters
Showing results (1-10 of 5) with videos related to
Page
of 1
Sort By:
Oncology (Williston Park, N.Y.)
|
April 18, 2016
Personalized Immune Therapy: A Slippery Fish?
Natasha B Hunter, Charles G Drake
Oncology (Williston Park, N.Y.)
|
January 4, 2018
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes
Natasha B Hunter, Samantha Vogt, Richard F Ambinder
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2020
The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility
Natasha B Hunter, Mark R Kilgore, Nancy E Davidson
Breast Cancer Research : BCR
|
February 18, 2025
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
Natasha B Hunter, Lanell M Peterson, Jennifer M Specht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Natasha B Hunter, Heather A Parsons, Leslie Cope, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 5) with videos related to
Sort By:
Page
of 1
Oncology (Williston Park, N.Y.)
|
April 18, 2016
Personalized Immune Therapy: A Slippery Fish?
Natasha B Hunter, Charles G Drake
Oncology (Williston Park, N.Y.)
|
January 4, 2018
Treatment of HIV-Associated Lymphomas: The Latest Approaches for Optimizing Outcomes
Natasha B Hunter, Samantha Vogt, Richard F Ambinder
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 30, 2020
The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility
Natasha B Hunter, Mark R Kilgore, Nancy E Davidson
Breast Cancer Research : BCR
|
February 18, 2025
Fluoroestradiol (FES) and Fluorodeoxyglucose (FDG) PET imaging in patients with ER+, HER2-positive or HER2-negative metastatic breast cancer
Natasha B Hunter, Lanell M Peterson, Jennifer M Specht, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 10, 2026
The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease
Natasha B Hunter, Heather A Parsons, Leslie Cope, et al.
Page
of 1